Azithromycin

Infectious Disease Specialist Calls Campaign against Repurposed Drugs in COVID-19 a ‘Great Hypocrisy’

Retrieved on: 
Thursday, March 21, 2024
Vanderbilt University, COVID, HCQ, Rheumatoid arthritis, Infection, Azithromycin, Lupus, Diabetes, COVID-19, Patient, Knowledge, Journal, Mortality, Addiction, Hydroxychloroquine, AAPS, Dysautonomia, Physician, Ivermectin, IVM, Pharmaceutical industry

Just before the death-knell announcement, Dr. Hoffman notes, substantial evidence favoring early use of HCQ had been submitted for publication by Dr. Harvey Risch of Yale.

Key Points: 
  • Just before the death-knell announcement, Dr. Hoffman notes, substantial evidence favoring early use of HCQ had been submitted for publication by Dr. Harvey Risch of Yale.
  • “In fact, all evidence is inherently flawed.”
    Dr. Hoffman points out how inconsistencies and double standards reveal the FDA’s hypocrisy regarding HCQ and ivermectin (IVM).
  • Paxlovid, he writes, has not been shown to be effective in hospitalized COVID patients, whereas the “flawed” study of HCQ demonstrated a greater than 60 percent benefit in reducing mortality.
  • “There is in fact a corpus of knowledge about the use of HCQ, IVM, and other off-label drugs, for example, at c19hcq.org, c19IVM.org18, and earlycovidcare.org,” Dr. Hoffman states.

Recce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 Against Gonorrhea

Retrieved on: 
Monday, December 18, 2023
ASX, RCE, Risk, WHO, Ageing, Vaginitis, Mouse, Gonorrhea, Infection, Neisseria gonorrhoeae, Azithromycin, World Health Organization, Safety, Ceftriaxone, Vaccine

“The need for a new class of anti-infectives could not be greater, especially against a sometimes lethal pathogen, such as N. gonorrhoeae,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.

Key Points: 
  • “The need for a new class of anti-infectives could not be greater, especially against a sometimes lethal pathogen, such as N. gonorrhoeae,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • After three days, the mice treated with R327 showed an approximate 4-log (99.99%) reduction in bacterial shedding, demonstrating significant bactericidal activity.
  • After five days of treatment, R327 showed a 3.5-log (>99.9%) reduction in bacterial shedding compared to the placebo-treated group.
  • A late-stage preclinical study comparing IV administration to a topical application of R327 against N. gonorrhoeae is underway.

Brightseed Receives $1.6 Million Grant to Improve Birth Outcomes by Supporting Undernourished Pregnant and Nursing Mothers

Retrieved on: 
Tuesday, December 19, 2023
Research, Philanthropy, Consumer, Technology, Artificial Intelligence, Fund Raising, Foundation, Science, Baby, Maternity, Women, Other Philanthropy, Other Science, Entrepreneurship, Woman, EED, Forager, Health, Malnutrition, Wasting, Artificial intelligence, Azithromycin, Infant, Bill, Mother, Therapy, Birth control

Bioactives company Brightseed today announces its second grant from the Bill & Melinda Gates Foundation .

Key Points: 
  • Bioactives company Brightseed today announces its second grant from the Bill & Melinda Gates Foundation .
  • Brightseed will use the $1.6 million funding to focus its artificial intelligence (AI) technology, Forager® , on identifying and validating natural bioactive compounds that target environmental enteric dysfunction (EED) in undernourished pregnant and lactating women, ultimately impacting global birth and infant outcomes.
  • EED is a poorly understood condition caused in part by micronutrient deficiencies, undernutrition, certain gut infections, and abnormal gut microbiota.
  • The project will ultimately result in candidate clinically effective nutritional products and potential therapeutics to support gut health in pregnant and lactating mothers in order to improve birth outcomes.

Petzey Addresses Unidentified Respiratory Illness Spreading Amongst Dogs

Retrieved on: 
Wednesday, December 13, 2023
Family, Health, Consumer, Infectious Diseases, Pets, Veterinary, Pet, Immune system, Pneumonia, Infection, Azithromycin, Chloramphenicol, Risk, Vaccination, Bordetella, Steroid, Weakness, Dehydration, Cold, Therapy, Human, Wheeze, Parent, Somatic symptom disorder, Dog, Lethargy, Vaccine, Doxycycline

Petzey , the leading on-demand mobile pet telehealth and wellness app, is addressing the recent outbreak of an unidentified respiratory illness affecting dogs across the country, from Oregon to Florida.

Key Points: 
  • Petzey , the leading on-demand mobile pet telehealth and wellness app, is addressing the recent outbreak of an unidentified respiratory illness affecting dogs across the country, from Oregon to Florida.
  • The condition, which has yet to be officially named, presents symptoms similar to known respiratory viruses and subsequent bacterial infections.
  • The illness can progress to pneumonia, posing a severe health risk.
  • Dr. Danny Cox, Chief Veterinary Medical Officer at Petzey, states, “What we understand about this new respiratory bug is its resemblance to other respiratory viruses like last year’s canine flu, canine parainfluenza, and treatable bacterial infections such as bordetella and pneumococcal pneumonia.

Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults

Retrieved on: 
Monday, October 30, 2023
Neoplasm, PDUFA, Food, Dysgeusia, Rash, Vitamin, Vonoprazan, Abdomen, Clarithromycin, Liver, Chills, Pain, Hypersensitivity, Infection, Allergy, Azithromycin, Rilpivirine, Diarrhea, Liver disease, Tablet, Medicine, Genetically modified bacteria, Drug, Safety, Patient, Chronic pain, DUAL, Catalent, History, Weight loss, Colchicine, GERD, Helicobacter pylori, Fever, Calcium channel, Common, PAS, Jaundice, CGA, Abdominal pain, FDA, Infectious mononucleosis, Headache, Aes, Skin, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Candidiasis, Erythromycin, Urine, Hypertension, Breast milk, Blood, AE, Pharmaceutical industry, Vaccine, Soft drink, Teahouse, Antibiotics, Medicinal plants, Dietary supplement, Birth control, Amoxicillin, Emtricitabine/rilpivirine/tenofovir

The full Prescribing Information for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK can be found here.

Key Points: 
  • The full Prescribing Information for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK can be found here.
  • VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) are co-packaged prescription medicines for the treatment of a Helicobacter pylori (H. pylori) bacterial infection in adults.
  • It is not known if VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK are safe and effective in children.
  • Stop taking VOQUEZNA TRIPLE PAK or VOQUEZNA DUAL PAK if you are diagnosed with mononucleosis and call your doctor right away.

Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea

Retrieved on: 
Wednesday, November 1, 2023
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Grand duchy, Food, Face, VWS, Disease, Gonorrhea, MHLW, Partnership, The Lancet, National Rural Development Partnership, Infection, Nursing care plan, Reproduction, SAMRC, Azithromycin, Hope, Physician, Prevalence, HIV, Ceftriaxone, BMBF, Neisseria gonorrhoeae, University, Therapy, Patient, Food and Drug Administration, Infertility, DFID, Heart, BMG, NIAID, MD, DHSC, AMR, BZ, Clinical trial, World Health Organization, Zoliflodacin, Woman, Multidrug-resistant bacteria, FOPH, South African Medical Research Council, Death, Ministry, Pharmaceutical industry, Vaccine, Medicine

These positive preliminary findings offer hope for patients with this condition, particularly in the face of rising antibiotic resistance to current regimens.

Key Points: 
  • These positive preliminary findings offer hope for patients with this condition, particularly in the face of rising antibiotic resistance to current regimens.
  • It also paves the way for a new research and development model in the global fight against antimicrobial resistance (AMR).
  • Now, the positive results of this landmark Phase 3 trial confirm that zoliflodacin has the potential to tackle the most difficult-to-treat gonorrhea infections.
  • This builds on the critical Phase 2 clinical trial sponsored by the U.S. National Institute of Allergy and Infectious Diseases (NIAID).

The FNIH Awards 2023 Charles A. Sanders, M.D., Partnership Award to NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development, GSK, and the O’Neill Family

Retrieved on: 
Monday, September 18, 2023
Children, Biotechnology, Baby, Maternity, Other Health, Health, Women, Pharmaceutical, Research, Consumer, Science, Clinical Trials, GSK, DNA, The New England Journal of Medicine, FNIH, Prevalence, Awards ceremony, Kidney cancer, Molina Healthcare, Clinical trial, Global Smoke-Free Partnership Award, Dean, Woman, Biomedical sciences, PRIORITY, Biomarker, NICHD, Lung, Doctor of Philosophy, Bill & Melinda Gates Foundation, Person, Bangladesh Technical Education Board, National Institutes of Health Clinical Center, Organization, NHLBI, Azithromycin, Charles, MD, Patient, Tuberculosis, World Cultural Council 29th Award Ceremony, Child, Anemia, Human development, Bill, Edmond, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Transplant, Death, NIH, National Heart, Lung, and Blood Institute, Renal cell carcinoma, Nursing, Pharmaceutical industry

The Foundation for the National Institutes of Health (FNIH) has named the National Institutes of Health’s Eunice Kennedy Shriver National Institute of Child Health and Human Development, GSK, and the O’Neill Family as recipients of the 2023 Charles A. Sanders, M.D., Partnership Award .

Key Points: 
  • The Foundation for the National Institutes of Health (FNIH) has named the National Institutes of Health’s Eunice Kennedy Shriver National Institute of Child Health and Human Development, GSK, and the O’Neill Family as recipients of the 2023 Charles A. Sanders, M.D., Partnership Award .
  • The Partnership Award recognizes persons or organizations that have made significant contributions to the FNIH’s work in support of the mission of the National Institutes of Health (NIH).
  • The Azithromycin Prevention in Labor Use Study (A-PLUS) assessed low-cost, sustainable interventions to improve maternal and child health.
  • The Charles A. Sanders, M.D., Partnership Award is named for the former Chairman of the FNIH Board of Directors.

Gates Foundation Goalkeepers Report Says Seven Innovations Could Save 2 Million Mothers and Babies by 2030

Retrieved on: 
Tuesday, September 12, 2023
Goalkeeper, United Nations Sustainable Development Group, Poverty, Pregnancy, IV, Education, Infection, Policy, COVID-19, Woman, Global health, Research, Melinda French Gates, Maternal death, Bill & Melinda Gates Foundation, Sustainable Development Goals, Mother, Death, Azithromycin, ACS, Child, Anemia, Internal bleeding, Bill, Mortality, Infant, United, Health, Food security, Coal, Birth control, Nursing, Dietary supplement

SEATTLE, Sept. 12, 2023 /PRNewswire/ -- The Bill & Melinda Gates Foundation today released its seventh annual Goalkeepers Report, describing where the world has collectively fallen short at the halfway point for achieving the United Nations Sustainable Development Goals (SDGs), and where innovation and investment can fuel progress, particularly in the fight against the global epidemic of maternal and child mortality.

Key Points: 
  • Co-authored by foundation Co-chairs Melinda French Gates and Bill Gates, the report highlights new data that shows the potential of scaling up global access to seven innovations and practices that address the leading causes of maternal and newborn deaths.
  • "By making new innovations accessible to those who need them most, 2 million additional lives could be saved by 2030, and 6.4 million lives by 2040.
  • That's 2 million families spared an unimaginable heartbreak—and 2 million more people who can shape and enrich our world," they write.
  • Many of the life-saving innovations and practices highlighted in the report can be delivered by midwives and birth attendants in communities.

Gates Foundation Goalkeepers Report Says Seven Innovations Could Save 2 Million Mothers and Babies by 2030

Retrieved on: 
Tuesday, September 12, 2023
Goalkeeper, United Nations Sustainable Development Group, Poverty, Pregnancy, IV, Education, Infection, Policy, COVID-19, Woman, Global health, Research, Melinda French Gates, Maternal death, Bill & Melinda Gates Foundation, Sustainable Development Goals, Mother, Death, Azithromycin, ACS, Child, Anemia, Internal bleeding, Bill, Mortality, Infant, United, Health, Food security, Coal, Birth control, Nursing, Dietary supplement

SEATTLE, Sept. 12, 2023 /PRNewswire/ -- The Bill & Melinda Gates Foundation today released its seventh annual Goalkeepers Report, describing where the world has collectively fallen short at the halfway point for achieving the United Nations Sustainable Development Goals (SDGs), and where innovation and investment can fuel progress, particularly in the fight against the global epidemic of maternal and child mortality.

Key Points: 
  • Co-authored by foundation Co-chairs Melinda French Gates and Bill Gates, the report highlights new data that shows the potential of scaling up global access to seven innovations and practices that address the leading causes of maternal and newborn deaths.
  • "By making new innovations accessible to those who need them most, 2 million additional lives could be saved by 2030, and 6.4 million lives by 2040.
  • That's 2 million families spared an unimaginable heartbreak—and 2 million more people who can shape and enrich our world," they write.
  • Many of the life-saving innovations and practices highlighted in the report can be delivered by midwives and birth attendants in communities.

Global Antibiotics Market Report 2023: Sector is Expected to Reach $68.04 Billion by 2030 at a CAGR of 4.26% - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 12, 2023
Health, Pharmaceutical, CDC, Antimicrobial spectrum, Prescription, Azithromycin, Physician, Pharmacy, USD, Pharmaceutical industry

The "Antibiotics Market Size, Share & Trends Analysis Report 2023-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Antibiotics Market Size, Share & Trends Analysis Report 2023-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global antibiotics market size is expected to reach USD 68.04 billion by 2030, registering a CAGR of 4.26% from 2023 to 2030, according to this report.
  • High demand, increasing focus on antibiotic resistance programs, initiatives undertaken to avoid the misuse of antibiotics, and easy availability of generic drugs are responsible for market growth.
  • According to the State of World's Antibiotics report, in 2021, the overall antimicrobial drug usage in India has increased sharply by 30%.